GSK2302032A Antigen-Specific cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
October 1, 2013
End Date
March 19, 2015
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
October 1, 2013
End Date
March 19, 2015